Arty Rajendra
Osborne Clarke LLPContinuing to expand its patent practice, the ‘switched on and collaborative’ team at Osborne Clarke LLP counts notable biotech and pharmaceutical clients among its key roster of clients, handling revocation and infringement proceedings on a global scale alongside technical commercial transactional mandates. Arty Rajendra heads up the group, fielding a strong practice on the SEP and FRAND disputes side, while Will James possesses a wealth of experience across the life sciences, electronics, and medical device sectors. Tim Harris drives life sciences, pharmaceutical, and biotech mandates for the team, and Trevor Crosse utilises his background in microbiology and immunology to handle blockbuster drugs and other technically complex products.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Very switched on and collaborative team. Extremely knowledgeable and hard working too.’
‘Will James, Trevor Crosse and their life science IP team are a strong team with broad expertise.'
'They rate very highly for their innovative and excellent solutions and ability to win cases and maximise opportunities.'
‘Will James is a first-rate litigator, able to see the big picture and bring innovative solution to the matters he manages. He can get the best out of people and teams, and his personable manner makes him a pleasure to work with.'
- 'Trevor Crosse has a real depth of knowledge across IP and regulatory life science. He is responsive, detail oriented and thorough.'
- 'I trust Trevor Crosse to get into the weeds on any issue and root out the key issues then provide pragmatic and actionable advice. Having Trevor in your team gives you a competitive edge and he is a pleasure to work with.'
Key clients
- Amgen
- Optis
- Avanci
- Kantar Group
- OMERS Life Sciences
- Santen
- Innovius
- Anstar Limited
Work highlights
- Advised Avanci on FRAND proceedings brought by Tesla.
- Advised OMERS Life Sciences on its acquisition of a portion of Enanta Pharmaceuticals' royalty entitlement for the antiviral medication Maviret.
- Advised Amgen on patent revocation and infringement proceedings against Janssen relating to Amgen's biosimilar version of the anti-IL12/IL23 antibody ustekinumab.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Arty Rajendra